Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 16/20 | 0.46 |
| ▸ | TSHR | P16473 | 10/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 12/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 11/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 9/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27756333 | 1.00 | CYP3A4 (0.46) | CYP3A4TSHRALDH1A1SMN1; SMN2CASP1 | |
| SCHEMBL27756338 | 1.00 | CYP3A4 (0.46) | CYP3A4TSHRALDH1A1SMN1; SMN2CASP1 | |
| SCHEMBL27756335 | 1.00 | CYP3A4 (0.46) | CYP3A4TSHRALDH1A1SMN1; SMN2CASP1 | |
| SCHEMBL12540247 | 1.00 | CYP3A4 (0.46) | CYP3A4TSHRALDH1A1SMN1; SMN2CASP1 | |
| SCHEMBL28580670 | 1.00 | CYP3A4 (0.46) | CYP3A4TSHRALDH1A1SMN1; SMN2CASP1 | |
| SCHEMBL13691987 | 1.00 | CYP3A4 (0.46) | CYP3A4TSHRALDH1A1SMN1; SMN2CASP1 | |
| SCHEMBL13534716 | 0.91 | CYP3A4 (0.46) | CYP3A4TSHRALDH1A1SMN1; SMN2CASP1 | |
| SCHEMBL20263087 | 0.90 | CYP3A4 (0.45) | CYP3A4TSHRALDH1A1SMN1; SMN2CASP1 | |
| SCHEMBL20263084 | 0.90 | CYP3A4 (0.45) | CYP3A4TSHRALDH1A1SMN1; SMN2CASP1 | |
| SCHEMBL12540565 | 0.89 | CYP3A4 (0.44) | CYP3A4TSHRALDH1A1SMN1; SMN2CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853224-B2 | Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases | INDUSTRIAL RESEARCH LIMITED (NZ) | 2014-10-07 | — | — | US | disclosed |
| US-8853224-B2 | Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases | INDUSTRIAL RESEARCH LIMITED (NZ) | 2014-10-07 | — | — | US | disclosed |
| US-20110130412-A1 | Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases | BIOCRYST PHARMACEUTICALS, INC. | 2011-06-02 | — | — | US | disclosed |
| US-20110130412-A1 | Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases | BIOCRYST PHARMACEUTICALS, INC. | 2011-06-02 | — | — | US | disclosed |
| WO-2008030119-A9 | ACYCLIC AMINE INHIBITORS OF NUCLEOSIDE PHOSPHORYLASES AND HYDROLASES | INDUSTRIAL RESEARCH LIMITED (NZ) | 2009-09-24 | — | — | WO | disclosed |
| EP-0984000-B1 | PROCESS FOR PRODUCING AMIDE DERIVATIVES AND INTERMEDIATE COMPOUNDS | JAPAN TOBACCO INC (JP) | 2008-12-03 | — | — | EP | disclosed |
| US-6194589-B1 | USEFUL AS AN HIV(HUMAN IMMUNODEFICIENCY VIRUS) PROTEASE INHIBITOR; AS X-RAY CONTRAST MEDIUM | JAPAN TOBACCO INC. (JP) | 2001-02-27 | — | — | US | disclosed |
| US-6121468-A | Process for producing amide derivatives and intermediate compounds | JAPAN TOBACCO INC. (JP) | 2000-09-19 | — | — | US | disclosed |
| EP-0984000-A1 | PROCESS FOR PRODUCING AMIDE DERIVATIVES AND INTERMEDIATE COMPOUNDS | Japan Tobacco Inc. (JP) | 2000-03-08 | — | — | EP | disclosed |
| US-6018066-A | Production of amide derivatives and intermediate compounds therefor | JAPAN TOBACCO INC. (JP) | 2000-01-25 | — | — | US | disclosed |
| US-5962704-A | Production of amide derivatives and intermediate compounds therefor | JAPAN TOBACCO INC. (JP) | 1999-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130412-A1 | Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases | PNP, TYMP, NTPCR | CYP3A4 1288/4885TSHR 3078/4885ALDH1A1 2065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.